The present findings showed that GP96 functions as an exacerbation factor for secondary bacterial infections following influenza; thus, we propose GP96 as a potential therapeutic target for novel countermeasures used to treat bacterial pneumonia. Here, HSP90B1 is linked to bacterial pneumonia.